Characteristics, Management and In-Hospital Clinical Outcomes Among Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: Results from the Phase I Data of ACURE Study

References

• Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2020report). Global Initiative for Chronic Obstructive Lung Disease (GOLD) Committees. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed April 28, 2020.
   Google Scholar
• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139(4):920–929. doi:10.1378/chest.10-1393
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2017 report). Global initiative for Chronic Obstructive Lung Disease (GOLD) Committees. .https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Accessed July 7, 2020.
   Google Scholar
• O’Donnell DE, Aaron S, Bourbeau J, et al. State of the Art Compendium: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. Can Respir J. 2004;11(Suppl B):7b–59b. doi:10.1155/2004/946769
   PubMedGoogle Scholar
• Simoens S. The economic burden of COPD exacerbations. COPD. 2010;7(3):159–161. doi:10.3109/15412555.2010.485098
   PubMedGoogle Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418–1422. doi:10.1164/ajrccm.157.5.9709032
   PubMed Web of Science ®Google Scholar
• Donaldson GC. COPD exacerbations {middle dot} 1: epidemiology. Thorax. 2006;61(2):164–168. doi:10.1136/thx.2005.041806
   PubMed Web of Science ®Google Scholar
• Tesfaigzi Y, Meek P, Lareau S. Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion. Clin Appl Immunol Rev. 2006;6(1):21–36. doi:10.1016/j.cair.2006.02.001
   PubMedGoogle Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613. doi:10.1164/ajrccm.161.5.9908022
   PubMed Web of Science ®Google Scholar
• Berkius J, Nolin T, Mardh C, Karlstrom G, Walther SM. Characteristics and long-term outcome of acute exacerbations in chronic obstructive pulmonary disease: an analysis of cases in the Swedish Intensive Care Registry during 2002–2006. Acta Anaesthesiol Scand. 2008;52(6):759–765. doi:10.1111/j.1399-6576.2008.01632.x
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955. doi:10.2147/COPD.S182905
   PubMed Web of Science ®Google Scholar
• Abadias Medrano MJ, Yuguero Torres O, Bardes Robles I, Casas-Mendez LF, Barbe F, de Batlle J. Exacerbations of chronic obstructive pulmonary disease: an analysis of the care process in a regional hospital emergency department. Medicine. 2018;97(31):e11601. doi:10.1097/MD.0000000000011601
   PubMed Web of Science ®Google Scholar
• Tabak YP, Sun X, Johannes RS, Gupta V, Shorr AF. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score. Arch Intern Med. 2009;169(17):1595–1602. doi:10.1001/archinternmed.2009.270
   PubMedGoogle Scholar
• Molinari N, Chanez P, Roche N, Ahmed E, Vachier I, Bourdin A. Rising total costs and mortality rates associated with admissions due to COPD exacerbations. Respir Res. 2016;17(1):149. doi:10.1186/s12931-016-0469-6
   PubMed Web of Science ®Google Scholar
• Breyer-Kohansal R, Hartl S, Breyer M-K, et al. The European COPD audit: adherence to guidelines, readmission risk and hospital care for acute exacerbations in Austria. Wien Klin Wochenschr. 2019;131(5–6):97–103. doi:10.1007/s00508-019-1441-5
   PubMed Web of Science ®Google Scholar
• Li X, Huang J, Zhang H. An analysis of hospital preparedness capacity for public health emergency in four regions of China: beijing, Shandong, Guangxi, and Hainan. BMC Public Health. 2008;8(1):319. doi:10.1186/1471-2458-8-319
   PubMed Web of Science ®Google Scholar
• Pei Z, Sun Y, Wang S, et al. Estimating mortality among inpatients with acute exacerbation of chronic obstructive pulmonary disease using registry data. NPJ Prim Care Respir Med. 2020;30(1):28. doi:10.1038/s41533-020-0186-y
   PubMed Web of Science ®Google Scholar
• Gu D, Kelly TN, Wu X, et al. Mortality attributable to smoking in China. N Engl J Med. 2009;360(2):150–159. doi:10.1056/NEJMsa0802902
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-3
   PubMed Web of Science ®Google Scholar
• Wan ES, Qiu W, Baccarelli A, et al. Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(12):1248–1255. doi:10.1164/rccm.201207-1280OC
   PubMed Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-30
   PubMed Web of Science ®Google Scholar
• Clinic M COPD diagnosis and treatment. Mayo Clinic. Available form: https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353685. Accessed May 27, 2020.
   Google Scholar
• Zhang J, Ou J-X, Bai C-X. Tobacco smoking in China: prevalence, disease burden, challenges and future strategies. Respirology. 2011;16(8):1165–1172. doi:10.1111/j.1440-1843.2011.02062.x
   PubMed Web of Science ®Google Scholar
• Esteban C, Castro-Acosta A, Alvarez-Martinez CJ, Capelastegui A, Lopez-Campos JL, Pozo-Rodriguez F. Predictors of one-year mortality after hospitalization for an exacerbation of COPD. BMC Pulm Med. 2018;18(1):18. doi:10.1186/s12890-018-0574-z
   PubMedGoogle Scholar
• Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017;12:3255–3262. doi:10.2147/COPD.S142997
   PubMed Web of Science ®Google Scholar
• Li X, Wu Z, Xue M, Du W. Smoking status affects clinical characteristics and disease course of acute exacerbation of chronic obstructive pulmonary disease: a prospectively observational study. Chronic Respir Dis. 2020;17:1479973120916184. doi:10.1177/1479973120916184
   Web of Science ®Google Scholar
• Xu F, Yin X, Shen H, Xu Y, Ware RS, Owen N. Better understanding the influence of cigarette smoking and indoor air pollution on chronic obstructive pulmonary disease: a case–control study in Mainland China. Respirology. 2007;12(6):891–897. doi:10.1111/j.1440-1843.2007.01178.x
   PubMed Web of Science ®Google Scholar
• Halbert RJ, Isonaka S, George D, Iqbal IA. Interpreting COPD prevalence estimates. Chest. 2003;123(5):1684–1692. doi:10.1378/chest.123.5.1684
   PubMed Web of Science ®Google Scholar
• Gaude GS, Bp R, Chaudhury A, Hattiholi J. Outcomes associated with acute exacerbations of chronic obstructive pulmonary disorder requiring hospitalization. Lung India. 2015;32(5):465–472. doi:10.4103/0970-2113.164150
   PubMedGoogle Scholar
• Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–760. doi:10.1164/rccm.200612-1749OC
   PubMed Web of Science ®Google Scholar
• Johansson G, Mushnikov V, Backstrom T, et al. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulm Med. 2018;18(1):17. doi:10.1186/s12890-018-0573-0
   PubMedGoogle Scholar
• Cao Z, Ong KC, Eng P, Tan WC, Ng TP. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology. 2006;11(2):188–195. doi:10.1111/j.1440-1843.2006.00819.x
   PubMed Web of Science ®Google Scholar
• Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475. doi:10.1183/09059180.00008612
   PubMedGoogle Scholar
• Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–1257. doi:10.1183/09031936.00133805
   PubMed Web of Science ®Google Scholar
• Xu Z, Zhao Z. Suggestions of including COPD into the scope of chronic disease outpatient reimbursement for residents’ medical insurance. Unity. 2018;216(03):60.
   Google Scholar
• Statistics N The per capita disposable income in China. National Bureau of Statistics. Available form: https://data.stats.gov.cn/easyquery.htm?cn=C01. Accessed Dec 9, 2020.
   Google Scholar
• Mereckiene J Seasonal influenza vaccination in Europe - overview of vaccination recommendations and coverage rates in the EU member states for the 2012–2013 influenza season, technical report. Eur Centre Dis Prev Control Web site. Available form: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf. Accessed Jul 21, 2020.
   Google Scholar
• Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147(4):894–942. doi:10.1378/chest.14-1676
   PubMed Web of Science ®Google Scholar
• Ciblak MA. Influenza vaccination in Turkey: prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine. 2013;31(3):518–523. doi:10.1016/j.vaccine.2012.11.022
   PubMed Web of Science ®Google Scholar
• Singapore Moh. MOH clinical practice guidelines 2/2017 chronic obstructive pulmonary disease executive summary. Ministry of health Singapore. Available form: https://www.moh.gov.sg/docs/librariesprovider4/guidelines/copd-cpg-2017_summary-card.pdf. Accessed May 6, 2020.
   Google Scholar
• Cerezo Lajas A, Gutiérrez González E, Llorente Parrado C, Puente Maestu L, de Miguel-díez J. Readmission due to exacerbation of COPD: associated factors. Lung. 2018;196(2):185–193. doi:10.1007/s00408-018-0093-y
   PubMed Web of Science ®Google Scholar
• CDC. Flu vaccination coverage, United States, 2014–15 influenza season. Available form: https://www.cdc.gov/flu/pdf/fluvaxview/NFID-coverage-2014-15-final.pdf. Accessed Jul 20, 2020.
   Google Scholar
• Wang Q, Yue N, Zheng M, et al. Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: a meta-analysis. Vaccine. 2018;36(48):7262–7269. doi:10.1016/j.vaccine.2018.10.045
   PubMed Web of Science ®Google Scholar
• Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease.. Cochrane Database Syst Rev. 2018;10:Cd010257. doi:10.1002/14651858.CD010257.pub2
   PubMedGoogle Scholar
• Butler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381(2):111–120. doi:10.1056/NEJMoa1803185
   PubMed Web of Science ®Google Scholar
• Cook R, Lyon-Maris J, White A. C reactive protein testing in general practice safely reduces antibiotic use for flare-ups of COPD. BMJ. 2019;367:l5991. doi:10.1136/bmj.l5991
   PubMedGoogle Scholar
• Wang J-X, Zhang S-M, Li X-H, Zhang Y, Xu Z-Y, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J Infect Dis. 2016;48:40–45. doi:10.1016/j.ijid.2016.04.024
   PubMed Web of Science ®Google Scholar